A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Oral Solabegron Modified Release Tablets in the Treatment of Overactive Bladder (OAB) in Adult Female Subjects
Phase of Trial: Phase II
Latest Information Update: 21 Aug 2019
Price : $35 *
At a glance
- Drugs Solabegron (Primary)
- Indications Overactive bladder
- Focus Therapeutic Use
- Acronyms VEL-2001
- Sponsors Velicept Therapeutics
- 16 Aug 2019 Status changed from active, no longer recruiting to completed.
- 23 Apr 2019 Planned End Date changed from 1 Mar 2019 to 1 May 2019.
- 23 Apr 2019 Planned primary completion date changed from 1 Mar 2019 to 1 Apr 2019.